Journal Mobile Options
Table of Contents
Vol. 114, No. 1, 2006
Issue release date: May 2006
Cytogenet Genome Res 114:89–92 (2006)

A 17q21.31 microdeletion encompassing the MAPT gene in a mentally impaired patient

Varela M.C. · Krepischi-Santos A.C.V. · Paz J.A. · Knijnenburg J. · Szuhai K. · Rosenberg C. · Koiffmann C.P.
aHuman Genome Study Center, and bLaboratory of Human Genetics, Department of Genetics and Evolutionary Biology, University of São Paulo, cNeurology Unit, Children Institute, University of São Paulo, School of Medicine, São Paulo (Brazil); dLaboratory of Cytochemistry and Cytometry, Department of Molecular Cell Biology, Leiden University Medical Center, Leiden (The Netherlands)

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


About 15% of patients with a clinical phenotype of Angelman syndrome (AS) have an unknown etiology. We report a patient with features reminiscent of AS, including a pattern of characteristic facial anomalies as well as speech impairment, developmental delay and frequent laughter. In addition, the patient had features not commonly associated with AS such as heart malformations and scoliosis. She was negative in SNURF-SNRPN exon 1 methylation studies and the G-banded karyotype was normal. Array-based comparative genomic hybridization disclosed a deletion of maximally 1 Mb at 17q21.31. The deleted region contains the MAPT gene, implicated in late onset neurodegenerative disorders, and the STH and NP_056258.1 genes. Another gene, such as CRHR1, might also be included based on maximum possible size of the deletion. We suggest that microdeletions within the 17q21.31 segment should be considered as a possible cause of phenotypes resembling AS, particularly when easily controlled seizures and/or cardiac abnormalities are also present.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Angelman H: Puppet children – A report on 3 cases. Develop Med Child Neurol 7:681–688 (1965).

    External Resources

  2. Carter NP, Fiegler H, Piper J: Comparative analysis of comparative genomic hybridization microarray technologies: report of a workshop sponsored by the Wellcome Trust. Cytometry 49:43–48 (2002).
  3. Ensembl:
  4. Fiegler H, Carr P, Douglas EJ, Burford DC, Hunt S, Smith J, et al: DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAC and PAC clones. Genes Chromosomes Cancer 36:361–374 (2003).
  5. Knijnenburg J, Szuhai K, Giltay J, Molenaar L, Sloos W, Poot M, Tanke HJ, Rosenberg C: Insights from genomic microarrays into structural chromosome rearrangements. Am J Med Genet A 132:36–40 (2005).
  6. Mickelson EC, Robinson WP, Hrynchak MA, Lewis ME: Novel case of del(17)(q23.1q23.3) further highlights a recognizable phenotype involving deletions of chromosome (17)(q21q24). Am J Med Genet 71:275–279 (1997).
  7. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P: Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28:53–67 (2000).
  8. Rosenberg C, Janson M, Nordeskjold M, Borresen AL, Vianna-Morgante AM: Intragenic reorganization of RB1 in a complex (4;13) rearrangement demonstrated by FISH. Cytogenet Cell Genet 65:268-271 (1994).
  9. Rosenberg C, Knijnenburg J, Bakker E, Vianna-Morgante A, Sloos WC, Otto PA, et al: Array-CGH detection of micro rearrangements in mentally retarded individuals: Clinical significance of imbalances present both in affected children and normal parents. J Med Genet 43:180–186 (2006).
  10. Shaw-Smith C, Redon R, Rickman L, Rio M, Willatt L, Fiegler H, et al: Microarray based comparative genomic hybridisation (array-CGH) detects submicroscopic chromosomal deletions and duplications in patients with learning disability/mental retardation and dysmorphic features. J Med Genet 41:241–248 (2004).
  11. Stefansson H, Helgason A, Thorleifsson G, Steinthorsdottir V, Masson G, Barnard J, et al: A common inversion under selection in Europeans. Nat Genet 37:129–137 (2005).
  12. Varela MC, Kok F, Otto PA, Koiffmann CP: Phenotypic variability in Angelman syndrome: comparison among different deletion classes and between deletion and UPD subjects. Eur J Hum Genet 12:987–992 (2004).
  13. Zeschnigk M, Lich C, Buiting K, Doerfler W, Horsthemke B: A single-tube PCR test for the diagnosis of Angelman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus. Eur J Hum Genet 5:94–98 (1997).

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00